Markers of HPV infection and survival in patients with head and neck tumors

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1832-1839

  Koslabova, Eva ^a,b   Hamsikova, Eva ^b   Salakova, Martina ^b   Klozar, Jan ^a   Foltynova, Eva ^a,b   Salkova, Eva ^c   Rotnaglova, Eliska ^a,b   Ludvikova, Viera ^b   Tachezy, Ruth ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

antibodies; follow up; head and neck cancer; HPV; oral rinses

Indexed keywords

E6 ANTIBODY; E7 ANTIBODY; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DNA DETERMINATION; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH HYGIENE; NONHUMAN; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; VIRUS CAPSID;

ANTIBODIES; FOLLOW-UP; HEAD AND NECK CANCER; HPV; ORAL RINSES;

ANTIBODIES, VIRAL; CAPSID PROTEINS; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; MOUTH; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; REPRESSOR PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84881555391     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28194     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Rotnaglova E, Tachezy R, Salakova M, et al. HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int J Cancer 2011; 129: 101-10.
3. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-Analysis of trends by time and region. Head Neck, in press. DOI: 10.1002/hed.22015.
4. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20.
5. Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3: S3-1-S310.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
7. Gillison ML,. HPV and prognosis for patients with oropharynx cancer. Eur J Cancer 2009; 45 Suppl 1: 383-5.
8. Mydlarz WK, Hennessey PT, Califano JA,. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin Med Diagn 2010; 4: 53-65.
9. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-44.
10. Rubenstein LM, Smith EM, Pawlita M, et al. Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study. Infect Agent Cancer 2011; 6: 9.
11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
12. Tachezy R, Klozar J, Rubenstein L, et al. Demographic and risk factors in patients with head and neck tumours. J Med Virol 2009; 81: 878-87.
13. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
14. Zhao M, Rosenbaum E, Carvalho AL, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer 2005; 117: 605-10.
15. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-55.
16. Smith EM, Ritchie JM, Pawlita M, et al. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 2007; 120: 825-32.
17. Chuang AY, Chuang TC, Chang S, et al. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol 2008; 44: 915-9.
18. Smith EM, Pawlita M, Rubenstein LM, et al. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 2010; 127: 111-7.
19. Baay MF, Duk JM, Burger MP, et al. Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up. Eur J Clin Microbiol Infect Dis 1999; 18: 126-32.
20. Hamsikova E, Ludvikova V, Tachezy R, et al. Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma. Int J Cancer 2000; 86: 351-5.
21. Di LA, Marcante ML, Poggiali F, et al. HPV 16 E7 antibody levels in cervical cancer patients: before and after treatment. J Med Virol 1998; 54: 192-5.
22. Agrawal Y, Koch WM, Xiao W, et al. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14: 7143-50.
23. Tachezy R, Klozar J, Salakova M, et al. HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis 2005; 11: 181-5.
24. Klozar J, Kratochvil V, Salakova M, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol 2008; 265 Suppl 1: S75-S82.
25. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
26. Manos MM, Wright DK, Lewis AJ, et al. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Mol Diagn Human Cancer 1989; 7: 209-14.
27. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
28. Munoz N, Bosch FX, de SS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
29. Parker TM, Smith EM, Ritchie JM, et al. Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors. Oral Oncol 2006; 42: 288-96.
30. Smith EM, Hoffman HT, Summersgill KS, et al. Human papillomavirus and risk of oral cancer. Laryngoscope 1998; 108: 1098-103.
31. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-36.
32. Zumbach K, Hoffmann M, Kahn T, et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-And-neck squamous-cell carcinoma. Int J Cancer 2000; 85: 815-8.
33. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-72.
34. Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441-50.
35. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of HR HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84: 796-801.
36. Costa S, De SP, Venturoli S, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003; 90: 358-65.